Physiologically based pharmacokinetic analysis of the concentration- dependent metabolism of halothane

References

• ANDES, M. W., 1991, Metabolism and toxicity of hydrochlorofluorocarbons: current knowledge and needs for the future. Environmental Health Perspectives, 96, 185–191.
   PubMedGoogle Scholar
• ANDERSEN, M. E., CLEWELL III, H. J., GARGAS, M. L., S mrrx, F. A. and REITZ, R. H., 1987, Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicological Applied Pharmacology, 87, 185–205.
   PubMed Web of Science ®Google Scholar
• BAKER, M. T., BATES, B. and LEFF, S. V., 1987, Stimulatory effects of halothane and isofluorane on fluoride release and cytochrome P-450 loss caused by metabolism of 2-chloro-1,1-difluoroethane, a halothane metabolite. Anesthetics and Analgesics, 66, 1141–1147.
   PubMedGoogle Scholar
• DODD, D. E., BRASHEAR, W. T. and VINEGAR, A., 1993, Metabolism and pharmacokinetics of selected halon replacement candidates. Toxicology Letters, 68, 37–47.
   PubMed Web of Science ®Google Scholar
• DUPPEL, W. and ULLRICH, V., 1976, Membrane effects on drug monooxygenation activity in hepatic microsomes. Biochirnica et Biophysica Acta, 426, 399–407.
   PubMed Web of Science ®Google Scholar
• ECKES, L. and Bucx, H. P., 1985, Influence of disulfiram, diethyldithiocarbamate and carbon disulfide on the metabolic formation of trifluoroacetic acid from halothane in the rat. Arzneirn Forsch. /Drug Research, 35, 1447–1451.
   PubMedGoogle Scholar
• FERGUSON, J. 1939, The use of chemical potentials as indices of toxicity. Proceedingsof the Royal Society, Series B, 127, 387–404.
   Google Scholar
• FISHER, J. W., WrrTAKER, T. A., TAYLOR, D. H., CLEWELL III, H. J. and ANDERSEN, M. E., 1989, Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicology and Applied Phar-macology, 89, 395–414.
   Google Scholar
• GANDOLFI, A. J., WffirE, R. D., SIPES, I. G. and PoHT, L. R., 1980, Bioactivation and covalent binding of halothane in vitro. Studies with [atI] and ["C]- halothane. Journal of Pharmacology and Experimental Therapeutics, 214, 721–725.
   PubMed Web of Science ®Google Scholar
• GARGAS, M. L., ANDERSEN, M. E. and CLEWELL III, H. J., 1986, A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicology and Applied Pharmacology, 86, 341–352.
   PubMed Web of Science ®Google Scholar
• GARGAS, M. L., BURGESS, R. J., VOISARD, D. E., CASON, G. H. and ANDERSEN, M. E., 1989, Partition coefficients of low-molecular weight volatile chemicals in various liquids and tissues. Toxicology and Applied Pharmacology, 98, 87–99.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN, D. B., 1984, The effects of drugs on membrane fluidity. Annual Reviews in Pharmacology and Toxicology, 24, 43–64.
   PubMed Web of Science ®Google Scholar
• GYLLEDHAAL O. and EHRSSON, H., 1975, Determination of sulphonamides by electron-capture gas chromatography. Preparation and properties of perfluoroacyl and pentafluorobenzyl derivatives. Journal of Chromatography, 107, 327–333.
   PubMedGoogle Scholar
• HARRIS, J. W. and ANDERS, M. W., 1991a, In vivo metabolism of the hydrochlorofluorocarbon 1,1-dichlo ro- 1-fluoroethane (HCFC- 141 b). Biochemical Pharmacology, 41, R13–16.
   PubMed Web of Science ®Google Scholar
• HARRIS, J. W. and ANDERS, M. W., 199 lb, Metabolism of the hydrochlorofluoro carbon 1,2- dichloro-1,1-difluoroethane. Chemical Research in Toxicology, 4, 180–186.
   Google Scholar
• HARRIS, J. W., JONES, J. P., MARTIN, J. L., LAROSA, A. C., OLSON, M. J., POHL, L. R. and ANDERS, M. W., 1992, Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid production with calculated enthalpies of activation. Chemical Research in Toxicology, 5, 720–725.
   PubMed Web of Science ®Google Scholar
• HARRIS, J. W., PoHL, L. R., MARTIN, J. L. and ANDERS, M. W., 1991, Tissue acylation by the chlorofluorocarbon substitute 2,2- dichloro-1,1,1- trifluoroethane. Proceedings of the National Academy Sciences USA, 88, 1407–1410.
   PubMed Web of Science ®Google Scholar
• HUWLYER, J., AFSCHLEVIANN, D., CHRISTEN, U. and GUT, J., 1992, The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chloro-fluorocarbon replacement 2,2- dichloro- 1,1,1- trifluoroethane. European Journal Biochemistry 207, 229–238.
   PubMedGoogle Scholar
• KATO, R. and YAMAZOE, Y., 1992, Sex- specific cytochrome P450 as a cause of sex- and species- related differences in drug toxicity. Toxicology Letters, 64/65, 661–667.
   Google Scholar
• KENNA, J. G., NEUBERGER, J. and WILLIAMS, R., 1987, Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. Journal of Pharmacology and Experimental Thera - peutics 242 733–740.
   PubMed Web of Science ®Google Scholar
• LIND, R. C. and GANDOLFI, A. J., 1993, Concentration-dependent inhibition of halothane bio-transformation in the guinea pig. Drug Metabolism and Disposition, 21, 386–389.
   PubMedGoogle Scholar
• LOIZOU, G. D. and ANDES, M. W., 1993, Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro- 1-fluoroethane (HCFC- 141b). Drug Metabolism and Disposition, 21, 634.
   PubMed Web of Science ®Google Scholar
• LOIZOU, G. D., URBAN, G., DEKANT, W. and ANDERS, M. W., 1994, Gas-uptake pharmacokinetics of 2,2-dichloro- 1,1,1- trifluoroethane (HCFC- 123). Drug Metabolism and Disposition, 22, 511–517.
   PubMed Web of Science ®Google Scholar
• LOIZOU, G. D., ELDIRDIRI, N. I. and KING, L. J., 1996, Physiologically based pharmacokinetics of uptake by inhalation of a series of 1,1,1- trihaloethanes: correlation with various physicochemical parameters. Inhalation Toxicology, 8, 1–19.
   Web of Science ®Google Scholar
• MANZER, L. E., 1990, The CFC- ozone issue: progress on development of alternatives to CFCs. Science, 249, 31–35.
   PubMed Web of Science ®Google Scholar
• OKIDA, M., KIKUCHI, H. and FUJII, K., 1986, Concentration-dependence of halothane metabolism in rabbits. Hiroshima Journal of Medical Science, 35, 15–20.
   PubMedGoogle Scholar
• ORTIZ DE MONTELLANO, P. R. and CORREIA, M. A., 1983, Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annual Reviews in Pharrnacologyand Toxicology23, 481–503.
   PubMed Web of Science ®Google Scholar
• RAMSEY, J. C. and ANDERSEN, M. E., 1984, A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicology and Applied Pharmacology 73, 159–175.
   PubMed Web of Science ®Google Scholar
• SIPES, I. G., GANDOLH, A. J., PoHL, L. R., KRISHNA, G. and BROWN, B. R., 1980, Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. Journal of Pharmacology and Experimental Therapeutics, 214, 716–720.
   PubMed Web of Science ®Google Scholar
• SKETT, P., 1988, Biochemical basis of sex differences in drug metabolism. Pharrnacologyand Therapeutics, 38, 269–304.
   PubMed Web of Science ®Google Scholar
• TIERNEY, D. J., HAAS, A. L. and KOOP, D. R., 1992, Degradation of cytochrome P4502E1 : selective loss after labilization of the enzyme. Archives of Biochemistry and Biophysics, 293, 9–16.
   PubMed Web of Science ®Google Scholar
• VAN DYKE, R. A. and GANDOLH, A. J., 1974, Studies on irreversible binding of radioactivity from [" C]halothane to rat hepatic micro somal lipids and protein. Drug Metabolism and Disposition, 2, 469–476.
   PubMedGoogle Scholar
• VERGANI, D., MIELI -VERGANI, G., ALBER1T, A., NEUBERGER, J., EDDLESTON, A. L. W. F., DAVIS, M. and WILLIAMS, R., 1980, Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. New England Journal of Medicine, 303, 66–71.
   Google Scholar
• VINEGAR, A., WILLIAMS, R. J., FISHER, J. W. and MCDOUGAL, J. N., 1994, Dose-dependent metabolism of 2,2-dichloro-1,1,1- trifluoroethane: a physiologically based pharmacokinetic model in the male Fischer 344 rat. Toxicology and Applied Pharmacology, 129, 103–113.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, R. J., VINEGAR, A., MCDOUGAL, J. N., JARABEcx, A. M. and FISHER, J. W., 1996, Rat to human extrapolation of HCFC- 123 kinetics deduced from halothane kinetics: a corollary approachtophysiologically based pharmacokinetic modeling. Fundamentals in Applied Toxicology, 30, 55–66.
   PubMedGoogle Scholar
• YAMAZOE, Y., MURAYAMA, N., SHIMADA, M., IMAOKA, S., FUNAE, Y. and KATO, R., 1989a. Suppression of hepatic levels of an ethanol-inducible P- 450DM A by growth hormone: relationship between the increased level of P- 450DM A and depletion of growth hormone in diabetes. Molecular Pharmacology, 36, 716–722.
   PubMedGoogle Scholar
• YAMAZOE, Y., MURAYAMA, N., SHWIADA, M., YAMAUCHI, K. and KATO, R., 1989b, Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Archives of Biochemistry and Biophysics, 268, 567–575.
   PubMed Web of Science ®Google Scholar